Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Stage of Development | 8 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Therapy Area | 9 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Indication | 10 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Companies | 13 | 2 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Companies Involved in Therapeutics Development | 22 | 9 |
| Bayer AG | 22 | 1 |
| Bharat Biotech International Limited | 23 | 1 |
| F. Hoffmann-La Roche Ltd. | 24 | 1 |
| Grifols, S.A. | 25 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 26 | 1 |
| Kedrion S.p.A. | 27 | 1 |
| Nostrum Pharmaceuticals, LLC | 28 | 1 |
| Omeros Corporation | 29 | 1 |
| ProMetic Life Sciences Inc. | 30 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Drug Profiles | 31 | 16 |
| alteplase Drug Profile | 31 | 2 |
| OMS-616 Drug Profile | 33 | 1 |
| plasminogen (human) Drug Profile | 34 | 1 |
| plasminogen (human) Drug Profile | 35 | 2 |
| plasminogen (recombinant) Drug Profile | 37 | 1 |
| Recombinant Prourokinase Drug Profile | 38 | 1 |
| Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder Drug Profile | 39 | 1 |
| SMRX-11 Drug Profile | 40 | 1 |
| TAL-0500018 Drug Profile | 41 | 2 |
| THR-100 Drug Profile | 43 | 1 |
| TMS-007 Drug Profile | 44 | 1 |
| tranexamic acid Drug Profile | 45 | 1 |
| TTS-01 Drug Profile | 46 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Dormant Projects | 47 | 2 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Discontinued Products | 49 | 1 |
| Plasminogen (Plasmin or PLG or EC 3.4.21.7) Featured News &Press Releases | 50 | 12 |
| Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA | 50 | 1 |
| May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA | 50 | 1 |
| May 10, 2016: Major new global study identifies a safer treatment of acute stroke | 51 | 1 |
| May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA | 52 | 1 |
| Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke | 53 | 2 |
| Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case | 55 | 1 |
| Nov 04, 2015: Prometic S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition | 56 | 1 |
| Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients | 56 | 1 |
| Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug | 57 | 1 |
| Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke | 58 | 1 |
| Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA | 58 | 1 |
| Aug 22, 2014: MHRA To Review Ischemic Stroke Drug | 59 | 1 |
| Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials | 59 | 2 |
| Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis | 61 | 1 |
| Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |